1.Xanthomas of the Bilateral Achilles Tendon in a Normolipidemic Patient.
Jung Woo LEE ; Jin Hyeok SEO ; Seung Suk SEO
Journal of Korean Foot and Ankle Society 2013;17(4):321-324
Xanthoma is a relatively rare soft tissue lesion on the Achilles tendon and is usually associated with hyperlipidemia (lipid metabolism abnormality), mental retardation, cataract and atherosclerotic disease. We report on a case of normolipidemic bilateral Achilles tendon xanthoma without any notable cause. We herein describe the case where we achieved a satisfactory result by subtotal resection.
Achilles Tendon*
;
Cataract
;
Humans
;
Hyperlipidemias
;
Intellectual Disability
;
Metabolism
;
Xanthomatosis*
2.Expression of nuclear factor-kappa B p65 in hyperlipemia model of mice.
Zhengde DU ; Qingsong YU ; Yi XIANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2010;24(7):289-292
OBJECTIVE:
To study the expression of nuclear factor kappa B p65 in hyperlipemia model of mice, and the relationship between hyperlipemia and deaf.
METHOD:
Twenty mice were divided into two group. The hyperlipemia diet group was established in ten mice,and the normal diet group was served as normal control. Six weeks later, immunohistostaining was used to detected the express of NF-kappa B p65 in all mouse cochlear. ABR threshold was obtained from both normal group and hyperlipemia group.
RESULT:
Immunoreactivity NF-kappa B p65 in mouse cochlea of hyperlipemia was localized in the organ of Corti, tectorial membrane, stria vascularis, spiral ligament, spiral ganglion and nerve fibers. The NF-kappa B p65 expression was markedly increased in mouse cochlea of hyperlipemia ABR threshold was significant difference between hyperlipemia group mice and control group mice (P < 0.01).
CONCLUSION
The expression of NF-kappa B p65 in mouse cochlea can be induced by hyperlipemia. And ABR threshold increased in hyperlipemia group mice. This shows that hyperlipidemia can damage acouesthesia of mice.
Animals
;
Cochlea
;
metabolism
;
Disease Models, Animal
;
Hyperlipidemias
;
metabolism
;
Mice
;
Mice, Inbred Strains
;
Transcription Factor RelA
;
metabolism
3.Discovery of biomarkers related to abnormal lipid metabolism in liver and serum and intervention mechanism of ginsenoside Rb_1 in hyperlipidemia rats based on non-targeted metabolomics.
China Journal of Chinese Materia Medica 2023;48(14):3922-3933
Through the non-targeted metabolomics study of endogenous substances in the liver and serum of hyperlipidemia rats, the biomarkers related to abnormal lipid metabolism in hyperlipidemia rats were found, and the target of ginsenoside Rb_1 in improving hyperlipidemia was explored and its mechanism was elucidated. The content of serum biochemical indexes of rats in each group was detected by the automatic biochemical analyzer. The metabolite profiles of liver tissues and serum of rats were analyzed by HPLC-MS. Principal component analysis(PCA) and orthogonal partial least squares-discriminant analysis(OPLS-DA) were used to compare and analyze the metabolic data in the normal group, the hyperlipidemia group, and the ginsenoside Rb_1 group, and screen potential biomar-kers. The related metabolic pathways were further constructed by KEGG database analysis. The results showed that hyperlipemia induced dyslipidemia in rats, which was alleviated by ginsenoside Rb_1. The non-targeted metabolomics results showed that there were 297 differential metabolites in the liver tissues of hyperlipidemia rats, 294 differential metabolites in the serum samples, and 560 diffe-rential metabolites in the hyperlipidemia rats treated by ginsenoside Rb_1. Perillic acid and N-ornithyl-L-taurine were common metabolites in the liver and serum samples, which could be used as potential biomarkers for ginsenoside Rb_1 in the improvement of hyperlipidemia. As revealed by pathway enrichment in the liver and serum, ginsenoside Rb_1 could participate in the metabolic pathway of choline in both the liver and serum. In addition, ginsenoside Rb_1 also participated in the ABC transporter, alanine, aspartic acid, and glutamate metabolism, protein digestion and absorption, β-alanine metabolism, taurine and hypotaurine metabolism, caffeine metabolism, valine, leucine, and isoleucine biosynthesis, arachidonic acid metabolism, and methionine and cysteine metabolism to improve dyslipidemia in rats.
Rats
;
Animals
;
Hyperlipidemias/drug therapy*
;
Metabolome
;
Ginsenosides/metabolism*
;
Lipid Metabolism
;
Metabolomics/methods*
;
Liver/metabolism*
;
Biomarkers
;
Taurine
4.Study on regulatory effect of Danshensu on lipid metabolism of hyperlipidemia rats.
Juan CHEN ; Jun DENG ; Yu-yan ZHANG ; Jian-guo LI ; Fei-yu WU ; Hai-tong WAN
China Journal of Chinese Materia Medica 2015;40(2):313-317
OBJECTIVETo explore the effect of Danshensu on the lipid metabolism of hyperlipidemic rats.
METHODSixty clean male SD rats were selected. Twelve of them were selected in the basic control group and fed with common foods, and the remaining rats were fed with the high-fat feeds. After the successful modeling, they were randomly divided into the high-fat control group and low dose (10 mg x kg(-1) x d(-1)), medium dose (20 mg x kg(-1) x d(-1)) and high dose (40 mg x kg(-1) x d(-1)) Danshensu (dissolved in saline) groups. Both of the two groups were abdominally injected with the same volume of normal saline once a day for consecutively 30 days. The serum TG, TC, HDL-C and liver ACC1, FAS, HMGR, CPT-I mRNA expressions were detected.
RESULT AND CONCLUSIONDanshensu could inhibit the LDL-C level, timely clear redundant cholesterol and effectively regulate the lipid metablism of hyperlipidemic rats by reducing the TC content, decrease the fatty acid by reducing the FAS mRNA expression, and reduce the synthesis levels of endogenous cholesterol by inhibit the HMGR mRNA expression.
Animals ; Hyperlipidemias ; drug therapy ; metabolism ; Lactates ; pharmacology ; Lipid Metabolism ; drug effects ; Male ; Rats ; Rats, Sprague-Dawley
5.An Update on Accumulating Exercise and Postprandial Lipaemia: Translating Theory Into Practice.
Masashi MIYASHITA ; Stephen F BURNS ; David J STENSEL
Journal of Preventive Medicine and Public Health 2013;46(Suppl 1):S3-S11
Over the last two decades, significant research attention has been given to the acute effect of a single bout of exercise on postprandial lipaemia. A large body of evidence supports the notion that an acute bout of aerobic exercise can reduce postprandial triacylglycerol (TAG) concentrations. However, this effect is short-lived emphasising the important role of regular physical activity for lowering TAG concentrations through an active lifestyle. In 1995, the concept of accumulating physical activity was introduced in expert recommendations with the advice that activity can be performed in several short bouts throughout the day with a minimum duration of 10 minutes per activity bout. Although the concept of accumulation has been widely publicised, there is still limited scientific evidence to support it but several studies have investigated the effects of accumulated activity on health-related outcomes to support the recommendations in physical activity guidelines. One area, which is the focus of this review, is the effect of accumulating exercise on postprandial lipaemia. We propose that accumulating exercise will provide additional physical activity options for lowering postprandial TAG concentrations relevant to individuals with limited time or exercise capacity to engage in more structured forms of exercise, or longer bouts of physical activity. The benefits of accumulated physical activity might translate to a reduced risk of cardiovascular disease in the long-term.
*Exercise
;
Humans
;
Hyperlipidemias/metabolism/pathology/*prevention & control
;
Lipid Metabolism
;
Postprandial Period
;
Triglycerides/blood
6.Study on anti-hyperlipidemia effect of Linderae Radix via regulating reverse cholesterol transport.
Hui-Fang LIU ; Jian-Bo HUANG ; Min-Cong HUANG ; Tao JIANG ; Gui-Yuan LYU ; Bo LI ; Xin-Yu QIU ; Bin CHENG ; Zhao-Huan LOU
China Journal of Chinese Materia Medica 2021;46(7):1795-1802
This article aims to investigate the ameliorative effect of Linderae Radix ethanol extract on hyperlipidemia rats induced by high-fat diet and to explore its possible mechanism from the perspective of reverse cholesterol transport(RCT). SD rats were divided into normal group, model group, atorvastatin group, Linderae Radix ethanol extract(LREE) of high, medium, low dose groups. Except for the normal group, the other groups were fed with a high-fat diet to establish hyperlipidemia rat models; the normal group and the model group were given pure water, while each administration group was given corresponding drugs by gavage once a day for five weeks. Serum total cholesterol(TC), triglyceride(TG), high density lipoprotein-cholesterol(HDL-c), low density lipoprotein-cholesterol(LDL-c), alanine aminotransferase(ALT), and aspartate aminotransferase(AST) levels were measured by automatic blood biochemistry analyzer; the contents of TC, TG, total bile acid(TBA) in liver and TC and TBA in feces of rats were detected by enzyme colorimetry. HE staining was used to observe the liver tissue lesions; immunohistochemistry was used to detect the expression of ATP-binding cassette G8(ABCG8) in small intestine; Western blot and immunohistochemistry were used to detect the expression of peroxisome proliferator-activated receptor gamma/aerfa(PPARγ/α), liver X receptor-α(LXRα), ATP-binding cassette A1(ABCA1) pathway protein and scavenger receptor class B type Ⅰ(SR-BⅠ) in liver. The results showed that LREE could effectively reduce serum and liver TC, TG levels, serum LDL-c levels and AST activity, and increase HDL-c levels, but did not significant improve ALT activity and liver index; HE staining results showed that LREE could reduce liver lipid deposition and inflammatory cell infiltration. In addition, LREE also increased the contents of fecal TC and TBA, and up-regulated the protein expressions of ABCG8 in small intestine and PPARγ/α, SR-BⅠ, LXRα, and ABCA1 in liver. LREE served as a positive role on hyperlipidemia model rats induced by high-fat diet, which might be related to the regulation of RCT, the promotion of the conversion of cholesterol to the liver and bile acids, and the intestinal excretion of cholesterol and bile acids. RCT regulation might be a potential mechanism of LREE against hyperlipidemia.
Animals
;
Biological Transport
;
Cholesterol/metabolism*
;
Diet, High-Fat/adverse effects*
;
Hyperlipidemias/metabolism*
;
Liver/metabolism*
;
Rats
;
Rats, Sprague-Dawley
;
Triglycerides/metabolism*
8.Effects of ginsenoside-Rb on blood lipid metabolism and anti-oxidation in hyperlipidemia rats.
Xin-mu ZHANG ; Shao-chun QU ; Da-yuan SUI ; Xiao-feng YU ; Zhong-zhi LV
China Journal of Chinese Materia Medica 2004;29(11):1085-1088
OBJECTIVETo observe effects of ginsenoside-Rb (G-Rb) on total cholesterol, lipoprotein cholesterol metabolism and anti-oxidation in experimental hyperlipidemia rats.
METHODHyperlipidemia rats were respectively given G-Rb 50, 100, 200 mg x kg(-1) x d(-1) ig for twelve days. Total cholesterol, lipoprotein cholesterol and lipid peroxidation (LPO) contents, prostacycline (PGI2), thromboxane (TXA2), superoxide dismutase (SOD) and blood viscosity were measured. Fat accumulation in liver was also observed.
RESULTTriglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c) in serum, TXA2 in plasma, LPO in serum and liver, and blood viscosity were decreased significantly. High density lipoprotein cholesterol (HDLc) in serum, PGI2 in plasma and SOD in serum and liver were significantly increased by G-Rb (100, 200 mg x kg(-1)) in experimental hyperlipidemia rats. In addition, G-Rb could decrease TC/HDL-c, LDLc/HDL-c ratio, increase PGI2/TXA2 ratio and inhibit fat accumulation in liver.
CONCLUSIONG-Rb could have anti-arteriosclerosis effect by improving cholesterol and lipoprotein-cholesterol metabolism, suppressing lipid peroxidation, increasing anti-oxidase activity and PGI2/TXA2 ratio.
Animals ; Antioxidants ; pharmacology ; Female ; Ginsenosides ; pharmacology ; Hyperlipidemias ; metabolism ; Lipid Peroxides ; metabolism ; Liver ; metabolism ; Male ; Rats ; Rats, Wistar
9.Expression of adipokines in children with primary nephrotic syndrome and its association with hyperlipidemia.
Ru-Xin ZHANG ; Xuan ZHANG ; Bi-Li ZHANG ; Zhu-Feng LIU ; Shu-Xiang LIN
Chinese Journal of Contemporary Pediatrics 2021;23(8):828-834
OBJECTIVES:
To study the expression of adipokines in children with primary nephrotic syndrome (PNS) before and after treatment and its correlation with blood lipids, as well as the role of adipokines in PNS children with hyperlipidemia.
METHODS:
A total of 90 children who were diagnosed with incipient PNS or recurrence of PNS after corticosteroid withdrawal for more than 6 months were enrolled as subjects. Thirty children who underwent physical examination were enrolled as the control group. Venous blood samples were collected from the children in the control group and the children with PNS before corticosteroid therapy (active stage) and after urinary protein clearance following 4 weeks of corticosteroid therapy (remission stage). ELISA was used to measure the levels of adipokines. An automatic biochemical analyzer was used to measure blood lipid levels.
RESULTS:
Compared with the control group, the children with PNS had a significantly lower level of omentin-1 in both active and remission stages, and their level of omentin-1 in the active stage was significantly lower than that in the remission stage (
CONCLUSIONS
Omentin-1 may be associated with disease activity, dyslipidemia, and proteinuria in children with PNS. Blood lipid ratios may be more effective than traditional blood lipid parameters in monitoring early cardiovascular risk in children with PNS.
Adipokines
;
Chemokines
;
Child
;
Cytokines/metabolism*
;
GPI-Linked Proteins/metabolism*
;
Humans
;
Hyperlipidemias
;
Lectins/metabolism*
;
Lipids
;
Nephrotic Syndrome/drug therapy*
;
Proteinuria
10.The Effects of Long Term Use of HMG-CoA Reductase Inhibitor on the Level of Lp (a).
Jin Won KIM ; Hong Seog SEO ; Sung Hee SIN ; Yung Jae OH ; Jung Chun AHN ; Eun Mi LEE ; Woo Hyuk SONG ; Young Hoon KIM ; Wan Joo SHIM ; Dong Joo OH ; Young Moo RO
Korean Circulation Journal 1999;29(12):1350-1356
BACKGROUND: Lipoprotein (a) concentration is mainly determined by apo (a) genotype, but elevated in the atherosclerotic vascular disease more than in normal group with the same apo (a) phenotype. It has been known that Lp (a) has independent metabolism in contrast with other lipoproteins and that the use of cholesterol lowering agent such as HMG-CoA reductase inhibitor for 6 months does not change the level of Lp (a). The results of several studies suggests that Lp (a) may be related to inflammation of atherosclerotic plaque and therefore, long term use of cholesterol lowering agents make plaque stable by reduction of inflammation at plaque. We hypothesized that there is a relationship between long term use of HMG-CoA reductase inhibitor and change of Lp (a) level. We prospectively measured Lp (a), lipids and inflammatory markers before and after long term use of HMG-CoA reductase inhibitor to examine our hypothesis. METHODS: Forty-nine subjects (M:F=28:21, age=59.1+/-12.0) with hyperlipidemia were administered HMG-CoA reductase inhibitor for 15 months (minimum 6 months, maximun 44 months), and Lp (a), lipids and inflammatory markers were measured before and after use of the HMG-CoA reductase inhibitor. In control group (ninty-nine subjects, M:F=60:39, age=61.2+/-9.2), these parameters were measured more than 6 months. RESULTS: In the hyperlipidemia group who were given HMG-CoA reductase inhibitor, baseline levels of total cholesterol, TG, LDL were significantly elevated more than those of the control group, but Lp (a) and inflammatory markers were not significantly different. After use of HMG-CoA reductase inhibitor, the level of Lp (a) was reduced significantly (before 28.9+/-29.3 mg/dl, after 20.0+/-19.0 mg/dl, p=0.009), but not significantly in the control group. There was a minimal relation between baseline Lp (a) levels and percent changes of Lp (a) levels. Total cholesterol and LDL levels reduced significantly after use of the drug, but inflammatory markers did not. CONCLUSION: These data showed that Lp (a) level in the hyperlipidemia group after the long term use of HMG-CoA reductase inhibitor decreased significantly. We suggest that these changes of Lp (a) level may be one of reliable markers for plaque stability in atherosclerotic vascular disease.
Atherosclerosis
;
Cholesterol
;
Genotype
;
Hyperlipidemias
;
Inflammation
;
Lipoprotein(a)
;
Lipoproteins
;
Metabolism
;
Oxidoreductases*
;
Phenotype
;
Plaque, Atherosclerotic
;
Prospective Studies
;
Vascular Diseases